This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
HomeSearch

Menu

Close

SerotypesSerotypesSerotype CoverageSerotype SelectionCase CoverageEfficacyEfficacyInvasive Pneumococcal DiseaseOtitis MediaClinical Trial Results

Clinical Trial
Results

Study DesignImmunogenicitySafety ProfileDosing & Recommendations

Dosing &
Recommendations

DosingAdherenceDisease BurdenDisease BurdenDisease BurdenDisparitiesAccess & SupportAccess &
SupportOrder Prevnar 20®Commercial health plansEventsMaterialsVideosGeneral Inquiries
Prescribing InformationPatient InformationIndications Patient Site
Focus on vaccine series completion disparities to help lower the risk of IPD1-3Many babies do not complete the recommended 4-dose PCV series1,2

While pneumococcal conjugate vaccines (PCVs) are recommended to be administered as a 4-dose series at 2, 4, 6, and 12 to 15 months of age, 1 in 5 babies (N=28,668) did not complete their PCV series by the time they were 24 months of age among babies born during 2020-2021 from the National Immunization Survey-Child.1,2*

Pneumococcal vaccination rates lag among babies who are publicly insured and those experiencing poverty1

Only 58% of uninsured babies (n=569) and 76% of Medicaid-eligible babies (n=10,018) receive ≥4 doses of a PCV by age 2 compared with 88% of children with private insurance (n=16,007) among babies born during 2020-2021 from the National Immunization Survey-Child.1*

Only 71% of babies experiencing poverty (n=4381) received the full PCV 4-dose series by age 2 compared with 85% of babies above the poverty line (n=23,369) among babies born during 2020-2021 from the National Immunization Survey-Child.1*

In some populations, vaccine uptake and series completion are below the national average1

Although routine childhood vaccination has led to substantial reductions in disease, vaccine uptake among some populations is suboptimal, leaving them at greater risk of diseases like IPD.1,3

Analyzing the disparities in PCVs

Disparities in PCV adherence are seen in certain racial/ethnic and socioeconomic groups.1

Your recommendation matters4Caregivers are likely to follow your lead:
  • Parents consider their child’s healthcare professionals to be their most trusted source of information when it comes to vaccines4
  • As a healthcare provider, your recommendation is important for supporting optimal vaccine uptake in your practice4
Remind caregivers that the 4th dose is needed to achieve optimal immune response and reinforce the importance of completing the 4-dose PCV series on time.2,5 Remind caregivers that the 4th dose is needed to achieve optimal immune response and reinforce the importance of completing the 4-dose PCV series on time.2,5 Find helpful resources for your practice Browse resources Disease BurdenIPD=invasive pneumococcal disease.
*Estimated vaccination coverage by age 24 months among babies born during 2020-2021 from the National Immunization Survey-Child, United States, 2021-2023. The Kaplan-Meier method was used to estimate vaccination coverage to account for babies whose vaccination history was ascertained before age 24 months.1
†These groups demonstrated statistically significant (P<0.05) differences in receiving 4 doses of a PCV by age 24 months compared with their reference groups.1References:Hill HA, Yankey D, Elam-Evans LD, et al. Decline in vaccination coverage by age 24 months and vaccination inequities among children born in 2020 and 2021 — National Immunization Survey-Child, United States, 2021–2023. MMWR Morb Mortal Wkly Rep. 2024;73(38):844–853.Farrar JL, Gierke R, Andrejko KL, et al. Use of 20-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072.Mohanty S, Done N, Liu Q, et al. Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998-2019. Vaccine. 2024;42(11):2758-2769.Centers for Disease Control and Prevention. Give a strong vaccine recommendation. June 18, 2024. Accessed April 28, 2025. https://www.cdc.gov/iqip/hcp/strategies/strong-vaccine-recommendation.htmlPrevnar 20® (Pneumococcal 20-valent Conjugate Vaccine) Prescribing Information. Wyeth Pharmaceuticals LLC, 2023.
Manufactured by Wyeth Pharmaceuticals LLC.
Marketed by Pfizer Inc.
PP-PNR-USA-2905 © 2025 Pfizer Inc.
All rights reserved. June 2025

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-PNR-USA-2905
You are now leaving PfizerPro
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
INDICATIONS 
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age
IMPORTANT SAFETY INFORMATION
  • Do not administer Prevnar 20® to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 20® or to diphtheria toxoid
  • Safety and immunogenicity data on Prevnar 20® are not available for individuals in immunocompromised groups, and vaccination should be considered on an individual basis. Based on experience with pneumococcal vaccines, individuals with altered immunocompetence may have reduced immune responses to Prevnar 20®
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and risks
  • In individuals 2, 4, 6, and 12 through 15 months of age vaccinated with a 4-dose schedule, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, decreased appetite, injection site redness, injection site swelling, and fever
  • In individuals 15 months through 17 years of age vaccinated with a single dose, the most commonly reported solicited adverse reactions (>10%) were irritability, pain at the injection site, drowsiness, fatigue and muscle pain, decreased appetite, injection site swelling and redness, headache, and fever
Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). ​​Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please click for Prevnar 20® Full Prescribing Information.INDICATIONSIndications
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
  • Prevnar 20® is a vaccine indicated for active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age